Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Currently, the quality outcome measures for palliative and end-of-life care focus more on end-of-life than upstream palliative care.

Outcomes for patients with hematologic malignancies appear to be worse across the board when managed by these measures compared with patients with solid tumors, says LeBlanc.

Videos

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.
 

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, gives advice on incorporating palliative care in the treatment of patients with hematologic malignancies.

LeBlanc says that medical oncologists should consider actively engaging palliative care specialists in the management of patients with hematologic malignancies.

It has been shown that patients undergoing stem cell transplant who were randomized to early concurrent palliative care experienced significant benefits in symptom management, quality of life, and a reduction in post-traumatic stress and depression.

Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, gives advice on incorporating palliative care in the treatment of hematologic malignancies.

Thomas W. LeBlanc, MD

Articles

Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

Dr. LeBlanc on Incorporating Palliative Care in the Treatment of Hematologic Malignancies